DeCure's autonomous Longevity AI scientist is researching a drug-repurposing hypothesis for age related macular degeneration 2 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAge related macular degeneration 2 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for age related macular degeneration 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ATP binding cassette subfamily A member 4 (ABCA4) — ABCA4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7M1Q · 2.92 Å · ligand [(2S)-3-[2-[(E)-[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenylidene]amino]ethoxy-oxidanyl-phosphoryl]oxy-2-[(Z)-octadec-9-enoyl]oxy-propyl] (Z)-octadec-9-enoate (HZL). Experimental structure, not a prediction.
What the evidence adds up to
Age-related macular degeneration is described as a leading cause of irreversible vision loss in the elderly and a severe public health problem. A 2001 review states the disease was then considered untreatable, with research focused on identifying genetic factors and molecular targets for early intervention. A 2021 overview confirms that current treatments have only been successful in delaying the loss of central vision, and that further research into pathophysiology, biomarkers, and potential therapeutic molecules is needed.
A 2024 analysis examines the role of dietary supplementation with vitamins and antioxidants in inhibiting the progression of AMD. The abstract notes considerable recent attention to this approach but provides no concrete data, no survival or response rates, and no sample sizes. It does not report any positive or negative results from any trial.
No evidence from these abstracts supports any drug or supplement as an effective treatment for age-related macular degeneration. The 2001 paper explicitly calls the disease untreatable, and the 2021 paper states that existing treatments only delay vision loss. What remains missing are completed, large-scale clinical trials with quantitative outcomes, adequate funding for such trials, and validated methods for stratifying patients by genetic or molecular subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Human Genetics · 2001 · 3 citations
The Genetic Epidemiology of Age-Related Maculopathy
AbstractAge-related maculopathy is a leading cause of blindness in the elderly. It is a major public health issue of increasing importance as populations become older. Currently considered untreatable, it is a complex disease associated with both genetic and environment factors. As currently reviewed, the importance of genetics in the etiology of age-related macular degeneration has been demonstrated by family studies, twin studies and segregation analysis. Ongoing research at the molecular level is endeavoring to isolate genes involved in the pathogenesis of this complex disease with the goal of identifying those individuals who are susceptible to impairment of visual function prior to overt manifestation of disease. The ultimate aim of this research is to identify molecular targets for appropriate and early therapeutic intervention.
Revista Brasileira de Oftalmologia · 2021 · 2 citations · open access
Age-related macular degeneration: an overview
AbstractAge-related macular degeneration is the most important cause of irreversible vision loss in the elderly and has been considered a severe public health problem. Current treatments have only been successful in delaying the loss of central vision. Due to increased life expectancy, governments and researchers have been challenged to seek more efficient and successful treatments for age-related macular degeneration. Considering its relevance for public health and the need of further research, this article aims to address age-related macular degeneration objectively, tackling on the current knowledge about its pathophysiology, potential molecular biomarkers, main prevention procedures and treatments, as well as introducing possible molecules that may be a therapeutic target in this disease.
Journal of Education Health and Sport · 2024 · 0 citations · open access
The Role of Dietary Supplementation in the Prevention of Macular Degeneration: An Analysis of the Efficacy of Vitamins and Antioxidants in Inhibiting the Progression of Macular Degeneration
AbstractAge-related macular degeneration (AMD), one of the leading causes of vision loss among the elderly, poses a significant global health issue. This is a retinal condition that causes the loss of central vision. The demographic shift towards an aging population contributes to the increasing number of individuals affected by this condition, presenting a challenge to the medical and scientific community in developing effective prevention and treatment methods. In recent years, considerable attention has been given to the role of a proper diet and the supplementation of vitamins and antioxidants in inhibiting the progression of AMD.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
